AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03905941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral combined hormonal contraceptives
Description: Oral combined hormonal contraceptive (OCs) with a combination of ethinyl estradiol 20 mcg/norethindrone acetate 1 mg will be used in this study. OCs are normally used to prevent pregnancy by suppressing ovulation and to prevent endometrial hyperplasia by inducing regular withdrawal bleeding. OCs help control both clinical and biochemical hyperandrogenism in PCOS and are considered first line medical therapy until the age of menopause.
Study NCT06180122 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Duplex ultrasound
Description: Vascular ultrasound scan of the left common iliac vein
Study NCT05940415 — intervention group
Intervention type: BEHAVIORAL
Intervention: active surveillance
Description: active surveillance without prostate biopsy
Study NCT05254340 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Inulin ingestion is not being used to diagnose, treat, or prevent irritable bowel syndrome. Inulin is being used to study an individual's ability to ferment dietary fiber.
Study NCT04972799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: injection of autologous fat at Day 0 and injection of saline at 6 months
Description: injection into the intersphincter space
Study NCT04972799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: injection of saline at Day 0 and injection of autologous fat at 6 months
Description: injection into the intersphincter space
Study NCT06607796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toluenesulfonamide (PTS) Intratumoral Injection
Description: intratumoral injection of toluenesulfonamide(PTS) to oligo lesions
Study NCT06587633 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endoscopic procedure
Description: tSVFem injection + 3D scaffold placement
Study NCT06613295 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SABR
Description: SABR
Study NCT06613295 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SABR
Description: SABR
Study NCT06149520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY3018250
Description: Dose 1 or dose 2 of BAY3018250
Study NCT06149520 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BAY3018250
Description: Matching placebo to BAY3018250
Study NCT06613295 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Separation surgery
Description: Separation surgery
Study NCT06611995 — intervention group
Intervention type: OTHER
Intervention: observational study
Description: Observational study without intervention
Study NCT06611852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Warm-up (5 minutes): Started with a 5-minute warm-up on the stationary bike at a low intensity to prepare the muscles for the workout.~Interval Training (15 minutes): Alternated between 1 minute of high-intensity cycling (pedaling at a faster pace with higher resistance) and 2 minutes of moderate-intensity cycling (steady pace with moderate resistance). This interval was repeated for a total of 15 minutes.~Hill Climbing (10 minutes): The resistance was increased on the stationary bike to simulate climbing a hill. Pedal at a slower pace but with higher resistance for 10 minutes to engage the muscles of legs and core.~Cool Down (5 minutes): The stationary cycling session was finished with a 5-minute cool down at a low intensity to gradually lower the heart rate and avoid fatigue.
Study NCT06611852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electronic cupping therapy in addition to aerobic exercise
Description: Four devices of electronic cupping therapy were equipped with 3.5-inch diameter cups (Becommend, model number: BE007, ASIN: B09PVF72RJ, China).
Study NCT06611852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interferential therapy in addition to aerobic exercise
Description: interferential current (Endomed 482, SN/29.382, Netherlands) was delivered by the following parameters: a carrier frequency of 5-kHz, a beat frequency of 80-160 Hz, and an intensity level below 33 mA. Four carbon rubber electrodes (8x12 cm) were used and fixed by a large abdominal strap with a wet spongy
Study NCT06611852 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interferential therapy, electronic cupping therapy in addition to aerobic exercises
Description: interferential therapy, electronic cupping therapy in addition to aerobic exercises
Study NCT06613113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: After receiving high and low dose radiotherapy on metastases, the enrolled patients will receive the combination of Fruquintinib and Adebrelimab. RECIST 1.1 standard was used for clinical tumor imaging evaluation every 6 weeks (±7 days). For complete response (CR) ,partial response (PR), or stable disease (SD), the enrolled patients will continue to receive the combination of Fruquintinib and Adebrelimab. Participants will receive the combination of Fruquintinib and Adebrelimab until disease progression or intolerable toxicity occurred.
Study NCT06611449 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The minimal flow anesthesia with sevoflurane group
Description: In the minimal flow group, anesthesia will be maintained with minimal fresh gas flow (0.3-0.5 L/min). The effect of minimal flow anesthesia on oxidative and neuroendocrine stress response will be evaluated by the levels of: IL-6 (proinflammatory cytokine), ACTH (adrenocorticotropic hormone), Cortisol, TAS/TOS (total antioxidant/oxidant status) measured from blood samples.~Blood samples will be taken from the antecubital area before the surgery begins, thus eliminating the need for repeated invasive procedures. Blood samples will be taken from the patients just before the surgery begins, at the end of the surgery, and at the 6th and 18th hours after the surgery.
Study NCT06611449 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The high flow anesthesia with sevoflurane group
Description: Maintenance of anesthesia in the high flow group will be provided with a high fresh gas flow (4 L/min). The effect of high flow anesthesia on oxidative and neuroendocrine stress response will be evaluated by the levels of: IL-6 (proinflammatory cytokine), ACTH (adrenocorticotropic hormone), Cortisol, TAS/TOS (total antioxidant/oxidant status) measured from blood samples.~Blood samples will be taken from the antecubital area before the surgery begins, thus eliminating the need for repeated invasive procedures. Blood samples will be taken from the patients just before the surgery begins, at the end of the surgery, and at the 6th and 18th hours after the surgery.
Study NCT06612593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: 2 tablets of 50 mg cilostazol will be received for 4 weeks, then the does will be 2 tablets of 100 mg cilostazol twice daily for 20 weeks
Study NCT06612593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The patient will receive 2 tablets twice daily
Study NCT06612593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: It includes Levodopa with a dose of 375 to 1000mg daily and Dopamine agonists with a dose of 1.5 to 5 mg daily.
Study NCT06612593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: It includes Levodopa with a dose of 375 to 1000mg daily and Dopamine agonists with a dose of 1.5 to 5 mg daily.
Study NCT05641844 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: RD2 Ver.02
Description: Debridement and suturing of the internal opening of the anal fistula and RD2 Ver.02 coagulating blood application into the fistula tract with a semi flexible cannula.
Study NCT05641844 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Saline
Description: Debridement and suturing of the internal opening of the anal fistula and Saline administration into the fistula tract with a semi flexible cannula.
Study NCT06333886 — intervention group
Intervention type: DEVICE
Intervention: Sacral electromyography
Description: Assessment of neuro-sacral function using point-of-care sacral surface electromyography
Study NCT04720989 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bathing With Baby Cleanser and water
Description: Late preterm and term newborns, whose informed consents are obtained by their parents to participate in the project, will be given their first baths according to the intervention group they are assigned to. Before the first bath / after birth, preterm newborns in all groups will be wiped only once with a clean towel without removing the vernix caseosa. Newborns who were bathed before the application of the study will be excluded from the study. As the most appropriate time for bath time, 30 minutes after the end of the feeding and treatment of the newborns, the bath application will be made at any time between 9 pm and 3 pm.
Study NCT04720989 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bathing With only Water
Description: Preterm infants will have their first baths only with water.
Study NCT05758818 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single dose of placebo on Day 1, Day 8 or Day 15 of part 2
Study NCT05758818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin (positive control)
Description: Participants will receive a single dose of moxifloxacin on Day 1,Day 8, or Day 15 of Part 2
Study NCT05758818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan
Description: Participants will receive a single dose of Milademetan on Day 1 for part 1~Participants will receive a single dose of milademetan on Day 1, Day 8, or Day 15 of Part 2
Study NCT06134661 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cTBS (continuous Theta Burst Stimulation)
Description: Continuous Theta Burst Stimulation (cTBS) is an inhibitory stimulation protocol of the Transcranial Magnetic Stimulation (TMS) device that temporarily inhibits brain activation in a small targeted brain area.~The investigators apply the cTBS protocol 3 times daily at 100% of the resting motor threshold (RMT) for 1500 pulses per session.
Study NCT06007846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Namenda
Description: Memantine 5 mg by mouth once daily, to be titrated up to 20 mg daily
Study NCT04940663 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: EMA
Description: Participants will complete surveys about their feelings and social habits through a smartphone app (EMA)
Study NCT05062746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matrix-Rhythm Therapy
Description: One session Matrix-Rhythm Therapy will be applied to affected body parts.
Study NCT05062746 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional physiotherapy and rehabilitation
Description: Hemiparetics wil receive one session conventional physiotherapy and rehabilitation.
Study NCT06437509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study NCT06437509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 monoclonal antibody
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study NCT04643327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Levetiracetam is currently approved in Australia and the U.S.A. for epilepsy. We will be providing levetiracetam in capsule form, 125mg levetiracetam in each capsule.
Study NCT04643327 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intervention will be maize-starch filled capsules with identical physical features to the active capsules.
Study NCT04692675 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: mpMRI
Description: 3T endorectal coil MR imaging of the prostate gland
Study NCT06474572 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct laryngoscope and table at xiphoid level
Description: Participants will be required to intubate the manikin with a direct laryngoscope and table at xiphoid level
Study NCT06474572 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Videolaryngoscope and table at xiphoid level
Description: Participants will be required to intubate the manikin with a video laryngoscope and table at xiphoid level
Study NCT06474572 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct laryngoscope and table at umbilical level
Description: Participants will be required to intubate the manikin with a direct laryngoscope and table at umbilical level
Study NCT06474572 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Videolaryngoscope and table at umbilical level
Description: Participants will be required to intubate the manikin with a videolaryngoscope and table at umbilical level
Study NCT04862234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dulaglutide
Description: A subcutaneous injection of dulaglutide 0.75 mg will be administered within 72 hours prior to a planned surgical intervention.
Study NCT04862234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A subcutaneous injection of a saline placebo will be administered within 72 hours prior to a planned surgical intervention.
Study NCT04862234 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitor (CGM), blinded
Description: Continuous glucose monitor (CGM) sensor will be placed preoperatively and continued during surgical hospitalization to monitor glucose levels. CGM provides an estimated capillary blood glucose (BG) level through direct measurement of interstitial glucose levels every 5-15 minutes.
Study NCT04862234 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Continuous glucose monitor (CGM), blinded
Description: Continuous glucose monitor (CGM) sensor will be placed preoperatively and continued during surgical hospitalization to monitor glucose levels. CGM provides an estimated capillary blood glucose (BG) level through direct measurement of interstitial glucose levels every 5-15 minutes.
Study NCT06254443 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Enema Bowel preparation
Description: Enema Group (Experimental Group): Enema is administered using either normal saline or 1% soapy water for cleansing until the effluent is clear of fecal debris, or until a total volume of 3000 ml of enema solution has been administered. The enema should be initiated 4-6 hours before colonoscopy, with the dosage and frequency of incremental enemas determined based on the patient's tolerance. The final enema administration should be completed no later than 10 minutes before the scheduled colonoscopy.
Study NCT06254443 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: PEG Bowel preparation
Description: Oral PEG Group (Control Group): Following the administration protocol recommended by the Chinese expert consensus for PEG, a 3 L PEG regimen is employed. The regimen involves segmented intake, with 1 L taken 10-12 hours before the intestinal examination and an additional 2 L taken 4-6 hours before the examination on the day of the procedure.
Study NCT05986552 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Schema Therapy (IST)
Description: IST is a form of empirically supported specialized psychotherapy for personality disorders. It is delivered in individual sessions by trained therapists.
Study NCT05986552 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual-Group Schema Therapy (IGST)
Description: IGST is a form of empirically supported specialized psychotherapy for personality disorders. It is delivered in the combination of individual sessions and group therapy sessions by trained therapists.
Study NCT06017258 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD371-specific/YSNVz/I-18 CAR T cells
Description: Cohorts will be infused with escalating doses of CD371-specific/YSNVz/IL-18 CAR T cells with lymphodepleting chemotherapy (LDC) to establish the maximum tolerated dose (MTD). There is a third, lower dose level (step-down dose) available for dose de-escalation in the event of severe toxicity at the first planned dose level.
Study NCT06414954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMD670
Description: Tablets taken twice a day for 21 days
Study NCT06414954 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets taken twice a day for 21 days
Study NCT06548854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STC314 Injection/STC314 Injection Placebo
Description: All subjects who meet the inclusion criteria and do not meet the exclusion criteria will be randomly assigned to receive continuous intravenous infusion of STC314 injection (dose in salt form) or placebo with continuous intravenous infusion of the same volume load infusion for 5 days at an overall ratio of 1:1:1.
Study NCT06548854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: STC314 Injection/STC314 Injection Placebo
Description: All subjects who meet the inclusion criteria and do not meet the exclusion criteria will be randomly assigned to receive continuous intravenous infusion of STC314 injection (dose in salt form) or placebo with continuous intravenous infusion of the same volume load infusion for 5 days at an overall ratio of 1:1:1.
Study NCT04407039 — intervention group
Intervention type: DEVICE
Intervention: PET/CT, H-MRS and MRI
Description: Use imaging methods to get metabolic parameters.
Study NCT05144555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fixed orthodontic treatment with stainless steel brackets
Description: Stainless steel brackets (Queen Series Low Profile Brackets MBT 0.022, Aestetika, Terni, TR, Italy) will be applied on the vestibular surfaces of teeth to perform orthodontic treatment.
Study NCT05144555 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fixed orthodontic treatment with ceramic brackets
Description: Ceramic brackets (Super Clear Series Brackets MBT 0.022, Aestetika, Terni, TR, Italy) will be applied on the vestibular surfaces of teeth to perform orthodontic treatment.
Study NCT05638295 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT05638295 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT05638295 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT05638295 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT05638295 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT05638295 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT05638295 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05638295 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT05638295 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Given IV
Study NCT05638295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotorasib
Description: Given PO
Study NCT05638295 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sotorasib
Description: Given PO
Study NCT06648473 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI Scan
Description: Subjects will begin the MRI with T1-pre, T2w, and volumetric 3D FLAIR images being obtained. The subject will be brought out of the MRI magnet and moved into a seated position and will then have a standard Brain Tumor Imaging Protocol MRI scan.
Study NCT04890236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: Given PO
Study NCT04890236 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Description: Given via infusion
Study NCT05611775 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Triaxial accelerometer
Description: Monitors placed on the waist, thigh, and bilateral ankles. Accelerometry will measure patients' physical activities in the free-living environment for 4 consecutive days. The patients will wear the monitor during waking hours and remove it during sleeping, showering, and swimming time.
Study NCT05931367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retatrutide
Description: Administered SC
Study NCT05931367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT05736692 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Sleep Intervention
Description: A \~50-minute semi-structured intervention based on the behavioral sleep medicine literature, particularly for adolescent insomnia, focused on key elements that can be addressed in one session. Treatment elements include engaging motivation, goal setting, barrier identification, problem-solving, pre-planning, self-monitoring, and setting rewards. The interventionist will be sensitized to barriers to sleep quality and quantity particularly relevant during adolescence, including job/work, homework, and social obligations, use of nicotine and caffeine, and social media and electronic devices. The interventionist will converse primarily with the adolescent, but parents will remain in the room as a support in problem-solving and executing therapeutic plans.